Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
BMC Oral Health ; 14: 14, 2014 Feb 20.
Artigo em Inglês | MEDLINE | ID: mdl-24552136

RESUMO

BACKGROUND: The isolation frequency and susceptibility to antifungal agents of oral Candida isolates from patients with oral candidiasis (OC) were compared between studies conducted in 2006-2007 and 2012-2013. METHODS: A total158 strains was isolated from 112 patients who visited Kagoshima University Hospital for the treatment of OC during the 14-month period from February 2012 and March 2013, and evaluated on the isolation frequency of each Candida strain and the susceptibility against antifungal drugs as compared to those evaluated in 2006-2007. RESULTS: There was a higher frequency of xerostomia as a chief complaint and of autoimmune disease in the 2012-2013 study than in the 2006-2007 study. More than 95% of Candida isolates were C. albicans and C. glabrata. In addition, the proportion of the latter increased from 12.3% in the 2006-2007 study to 23.4% in the 2012-2013 study, while the proportion of the former decreased from 86.2% to 72.8%, respectively. C. albicans was isolated in almost all patients, while C. glabrata was only isolated concomitantly with C. albicans. Minimal inhibitory concentrations (MICs) were not significantly different between groups with a few exceptions. Candida isolates, of which MICs surpassed break points, apparently increased for miconazole and itraconazole against C. glabrata in the 2012-2013 study, but this was not statistically significant. As a result, more cases of autoimmune disease, a greater number of C. glabrata isolates, and higher resistance to azoles were seen in the 2012-2013 study than in the 2006-2007 study. CONCLUSION: These data indicate that with recent increases in C. glabrata infection, a causative fungus of OC, and in C. glabrata resistance to azoles, caution is needed in the selection of antifungal drugs for the treatment of OC.


Assuntos
Antifúngicos/uso terapêutico , Candida/isolamento & purificação , Candidíase Bucal/microbiologia , Farmacorresistência Fúngica , Adulto , Idoso , Idoso de 80 Anos ou mais , Anfotericina B/uso terapêutico , Doenças Autoimunes/microbiologia , Carga Bacteriana , Candida/classificação , Candida/efeitos dos fármacos , Candida albicans/efeitos dos fármacos , Candida albicans/isolamento & purificação , Candida glabrata/efeitos dos fármacos , Candida glabrata/isolamento & purificação , Candidíase Bucal/tratamento farmacológico , Coinfecção/microbiologia , Equinocandinas/uso terapêutico , Feminino , Fluconazol/uso terapêutico , Flucitosina/uso terapêutico , Humanos , Itraconazol/uso terapêutico , Japão , Lipopeptídeos/uso terapêutico , Masculino , Micafungina , Miconazol/uso terapêutico , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Xerostomia/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA